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Irvine, 17.0 % (40/235) and 12.1 % (40/330) for Vitrolife,
21.4 % (39/182) and 9.9 % (39/395) for slow-freezing (NS).
Conclusions Both vitrification methods (Irvine and Vitrolife)
are more efficient than slow freezing for cryopreservation of
human cleavage stage embryos in terms of post-warming
survival rate. No significant difference in the implantation rate
was observed between the three cryopreservation methods.
Keywords Human cleavage stage embryo . Vitrification .
Slowfreezing .Survival andcleavagerates .Clinicaloutcomes
Introduction
In vitro fertilization (IVF) cycles are often characterised by the
production of excess human embryos which can be cryopre-
served and used for the patients to achieve pregnancy in
subsequent warming cycles [1]. Embryo cryopreservation
improves the cumulative pregnancy rate per IVF cycle
allowing additional chances of pregnancy without re-
exposure to exogenous gonadotropins and subsequent oocyte
retrieval procedure. Embryo cryopreservation allows to per-
form fresh elective single embryo transfer (SET), avoiding
multiple gestations [2–5]. Embryo freezing is also used as
strategy to prevent ovarian hyperstimulation syndrome [6–8]
or to delay embryo transfer if endometrial preparation is not
optimal [9, 10]. The first report of successful pregnancy from
transferred cryopreserved human embryos was published
29 years ago [11]. Since then, cryopreservation became es-
sential in assisted reproductive technologies to optimize the
efficiency of IVF cycles [12–15]. Conventional slow-freezing
protocols have been extensively used for cryopreservation of
human embryos. These procedures are based on low cryopro-
tectant concentrations and a slow cooling rate. Vitrification is
an increasingly popular method, based on an extreme viscos-
ity of cryoprotectant solutions and a high cooling rate. The
Capsule Through a higher survival rate and quality of cleavage stage
embryos at warming, vitrification may improve the clinical outcome of
IVF by maximizing the efficiency of the cycle.
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Abstract
Purpose To compare two different vitrification methods to
slow freezing method for cryopreservation of human cleavage
stage embryos. Design: Prospective randomised trial. Setting:
University assisted reproduction centre. Patient(s): 568 pa-
tients (mean age 33.4±5.2) from April 2009 to April 2011.
Methods 1798 supernumerary good-quality cleavage stage
embryos in 645 IVF cycles intended to be cryopreserved were
randomly allocated to three groups: slow freezing, vitrification
with the Irvine® method, vitrification with the Vitrolife®
method. Main Outcome Measure(s): Embryo survival and
cleavage rates, implantation rate.
Results A total of 1055 embryos were warmed, 836 (79.2 %)
survived and 676 were finally transferred (64.1 %). Post-
warming embryos survival rate was significantly higher after
vitrification (Irvine: 89.4 %; Vitrolife: 87.6 %) than after slow
freezing (63.8 %) (p <0.001). No differences in survival rates
were observed between the two vitrification methods, but a
significant higher cleavage rate was observed using Irvine
compared to Vitrolife method (p <0.05). Implantation rate
(IR) per embryo replaced and per embryo warmed were
respectively 15.8 % (41/259) and 12.4 % (41/330) for
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assessment of benefits/risks as well as cost/efficiency of the
different cryopreservation methods has been recently
reviewed [16–18]. Both procedures have advantages and lim-
itations and at present, a wide variety of cryopreservation
protocols of slow-freezing and vitrification are available.
The main issue during embryo cryopreservation procedure,
in both cooling and warming steps, are the chilling injury, the
intracellular ice formation, and the fracture damages [19, 20].
To overcome them, all cryopreservation strategies are using
different cryoprotectant solutions and cooling-warming rates.
Vitrification has been extensively tested on human blastocyst
stage embryos [21–23]. Vitrification has also been applied
successfully for the cryopreservation of human cleavage stage
embryos [24, 25]. It has to be noted that improved slow-
freezing methods can produce comparable results [26, 27].
However, there are still only few randomized clinical trials
addressing the optimal method of cryopreservation for human
cleavage stage embryos [28–30].
The aim of this study was to compare the slow-freezing
method usually performed in our Fertility Clinic for cryopres-
ervation of human cleavage stage embryos to two different
vitrification methods using commercially available media.
High security devices were used for all procedures. Data
analyzed included survival rate, cleavage rates of embryo after
warming and clinical outcomes after transfer.
Materials and methods
The study was approved by the Ethics Committee of Hospital
and conducted at the Fertility Clinic from April 2009 to April
2011.
Before starting their IVF cycle, patients were thoroughly
informed about the comparative trial and signed written con-
sent forms. None of the patients refused to participate. All
patients undergoing an IVF treatment during this period,
including oocyte recipients, were recruited in the study.
Exclusion criteria were limited to cycles without good-
quality supernumerary embryos and cycles from our special
programs as infected patients (HIV, hepatitis B or C) and
Preimplantation Genetic Diagnosis. Embryos were scored
according to our grading system on the day of embryo transfer
[31] and good-quality supernumerary embryos were allocated
to one of the three groups for cryopreservation. A good-
quality embryo is defined as timely cleaved (day 2: 4–6 cell;
day 3: 8–12 cells) and with equal-size and shaped blastomeres
and/or <30 % of fragmentation.
During the study period, a total of 1798 supernumerary
good-quality day 2 or day 3 cleavage stage embryos from 645
fresh IVF cycles of 568 patients (mean age 33.4 years±5.2),
according to a previously established weekly basis, were
allocated to three cryopreservation groups: vitrification with
the Irvine® procedure and media (Irvine group), vitrification
with the Vitrolife® procedure and media (Vitrolife group) and
slow-freezing procedure and media (slow-freezing group).
The storage was performed using the Vitrification High
Security kits and the High Security straws from
CryoBioSystem® for vitrification and for slow-freezing
groups, respectively.
The mean age of patients in the cryopreservation cycles
(Irvine group: 33.7 years±5.4; Vitrolife group: 33.6 years±
5.2; slow-freezing group: 33.1 years±5.0) was similar in all
groups. The mean age of the donors (Irvine group: 31.0 years
±4.2; Vitrolife group: 31.9 years±3.5; slow-freezing group:
31.4 years±5.3) and the proportion of cycles with frozen
embryos obtained from oocyte donation was similar between
the three studied groups (Irvine group: 12/255; Vitrolife
group: 16/261; slow-freezing group: 18/260).
At the time of analysis (October 2012), 1055 of these
embryos (58.6 %) were warmed for transfer in 776 initiated
warming cycles of 420 patients (mean age 34.1±5.2). Patient
characteristics in the warming groups were similars. Of the all
embryos included in the data analysed, 913/1055 were at day
2 cleavage stage and 142/1055 were at day 3 cleavage stage
and the proportion of day 3 embryos was similar between the
three different groups (Irvine: 45/330; Vitrolife: 37/330; slow-
freezing: 60/395). Among all embryos warmed, 915/1055
were at 4–6 cells at cooling, only 16/1055 were at 2 cells
and 124/1055 were at 8–12 cells. The efficacy of the three
cryopreservation methods was assessed on these 1055
warmed embryos in terms of embryo survival and cleavage
rates and in terms of implantation and live birth rates.
Stimulation protocol for IVF
GnRH agonist and antagonist protocols were both used for
controlled ovarian stimulation with urinary gonadotropins
(hMG: Menopur®, Ferring, Switzerland) or recombinant
FSH (Gonal F®, Merck-Serono, Switzerland or Puregon®,
MSD, USA). Pituitary desensitization was obtained either
using gonadotropin-releasing hormone agonists (Buserelin
acetate: Suprefact® spray, Hoechst Inc., Germany or
Triptorelin: Decapeptyl®, Ipsen, France) in short and long
protocols or GnRH antagonist (Cetrorelix: Cetrotide®,
Merck-Serono, Switzerland or Ganirelix: Orgalutran®,
MSD, USA) started after 5 days of ovarian stimulation.
When at least 3 follicles reached 17mm in diameter, ovulation
was induced by the administration of urinary human chorionic
gonadotropin (hCG: Pregnyl®, MSD, USA) or recombinant
hCG (Ovitrelle®, Merck-Serono, Switzerland). Oocyte re-
trieval was performed through vaginal puncture under ultra-
sound guidance 36 h later. Oocyte collection and laboratory
procedures are described elsewhere [32].
For the warming cycles, patients underwent endometrial
preparation for embryo transfers with either natural cycle or
hormone therapy cycle (estradiol valerate: Progynova®,
Irvine vitrification procedure and media (Irvine group) The
technique of vitrification was performed according to the
manufacturer’s instructions at room temperature. Embryos
were placed into the Equilibration Solution (ES) for 5 min
and then into the Vitrification Solution (VS) for 90 s. These
solutions were used in sequence according to the step-wise
microdrop vitrification protocol as described in the commer-
cial kit instructions. ES is a HEPES buffered solution of
Medium-199 containing gentamicin sulfate (35 μg/mL),
7.5 % (v/v) of each DMSO and ethylene glycol and 20 %
(v/v) Dextran Serum Supplement. VS is a HEPES buffered
solution of Medium-199 containing gentamicin sulfate
(35 μg/mL), 15 % (v/v) of each DMSO and ethylene glycol,
20 % (v/v) Dextran Serum Supplement and 0.5 M sucrose.
The embryos were loaded in high security straws (Vitrification
High Security kits from CryoBioSystem) in a volume of
maximum 1 μl. Straws were quickly plunged into Liquid
Nitrogen (LN2) vertically and gently stirred in LN2 for a few
seconds, then placed into the submerged LN2 filled cryotube
into the cryo-freezer for long-term storage.
Irvine warming procedure and media The technique of
warming was performed according to the manufacturer’s in-
structions. Straws were removed from the cryotube and
dipped into the Thawing Solution (TS) for 1 min at 37 °C.
TS is a HEPES buffered solution of Medium-199 containing
gentamicin sulfate (35 μg/mL), 1.0 M sucrose and 20 % (v/v)
Dextran Serum Supplement. Embryos were placed succes-
sively into the Dilution Solution (DS) for 4 min and the
washing solution (WS) for 9 min at room temperature. DS is
a HEPES buffered solution of Medium-199 containing genta-
micin sulfate (35 μg/mL), 0.5 M sucrose and 20 % (v/v)
Dextran Serum Supplement. WS is a HEPES buffered solu-
tion of Medium-199 containing gentamicin sulfate (35 μg/
mL) and 20 % (v/v) Dextran Serum Supplement. Finally,
embryos were transferred to a pre-equilibrated culture dish
containing microdrops of cleavage medium (day 2 cleavage
stage) or blastocyst medium (day 3 cleavage stage) (Cook,
Australia).
Vitrolife vitrification procedure and media (Vitrolife
group) The entire procedure was performed at 37 °C accord-
ing to the manufacturer’s instructions. Embryos were placed
into the Vitri 1™Cleave Solution for 5 min, then into the Vitri
2™ Cleave Solution for 2 min, and finally into the Vitri 3™
Cleave Solution for 30 s.
The three solutions consist of a MOPS buffered medium
containing gentamicin and human serum albumin. Vitri 1™
Cleave doesn’t contain any cryoprotectants, Vitri 2™ Cleave
contains ethylene glycol as a cryoprotectant and Vitri 3™
Cleave contains ethylene glycol, propanediol, ficoll and su-
crose as cryoprotectants. Cryoprotectants concentration is not
detailed in the commercial kits. The embryos were loaded in
high security straws (Vitrification High Security kits,
CryoBioSystem) in a volume of maximum 1 μl. Straws were
quickly plunged into Liquid Nitrogen (LN2) vertically and
gently stirred in LN2 for a few seconds, then placed into the
submerged LN2 filled cryotube into the cryo-freezer for long-
term storage.
Vitrolife warming procedure and media The technique of
warming was performed according to the manufacturer’s in-
structions using the RapidWarm™ Cleave kit consisting of
four different warming solutions. The entire procedure was
performed at 37 °C. Straws were removed from the cryotube
and dipped into theWarm1™ solution for 10 to 30 s, then into
the Warm2™ solution for 1 min, after that into the Warm3™
solution for 2 min and finally into the Warm4™ solution for
5 min. The solutions consist of a MOPS buffered medium
containing gentamicin and human serum albumin. Warm 1™
Cleave, Warm 2™ Cleave, Warm 3™ Cleave contain sucrose
as a cryoprotectant while Warm 4™ Cleave contains no
cryoprotectants. Cryoprotectants concentration is not detailed
in the commercial kits. Finally, embryos were transferred to a
pre-equilibrated culture dish containing microdrops of cleav-
age medium (day 2 cleavage stage) or blastocyst medium (day
3 cleavage stage) (Cook, Australia)
Slow-freezing method
Freezing procedure and media (slow-freezing group) The
entire procedure was performed at room temperature.
Embryos were placed for 10 min into a home-made freezing
solution consisting of a manufactured buffered medium
(Lonza, Belgium) containing gentamicin (40 μg/mL) and
0.5 % human serum albumin (CAF-DCF, Belgium) supple-
mented with 1.5 M 1,2-propanediol (PROH) and 0.1 M su-
crose (Sigma–Aldrich S.r.L., UK). Embryos were then loaded
into 0.3 ml high security straws (High Security straws,
CryoBioSystem) and placed into the embryo freezer machine
(BD1, Biotronics, UK). The programmed cooling curve was:
from 25 °C to −7 °C (rate −2 °C/min), 15 min at −7 °C,
seeding, 15 min at −7 °C, from −7 °C to −35 °C (rate
−0.3 °C/min), from −35 °C to −80 °C (rate −45 °C/min).
Finally straws were placed into the submerged LN2 filled
cryotube into the cryo-freezer for long-term storage.
Thawing procedure and media Straws were removed from
the cryotube and, after 30 s at room temperature, plunged into
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Schering, Belgium). The luteal phase was supported with
micronized progesterone (Utrogestan®, Besins-Iscovesco,
France) in separate doses of 2×200 mg in natural cycle and
3×200 mg in hormone cycle.
Vitrification methods
a water bath for 5 s at 30 °C. Embryos were released into a
home-made thawing solution consisting of buffered medium
(Lonza, Belgium) containing gentamicin (40 μg/mL) and
0.5 % human serum albumin (CAF-DCF, Belgium) supple-
mented with 0.5 M sucrose (Sigma–Aldrich S.r.L., UK).
Finally, embryos were transferred to a pre-equilibrated culture
dish containing microdrops of cleavage medium (day 2 cleav-
age stage) or blastocyst medium (day 3 cleavage stage) (Cook,
Australia).
Embryo survival assessment and handling
Embryos were warmed the day before transfer, and were
considered to have survived if they had 50 % or more surviv-
ing cells, evaluated as the absence of overt individual blasto-
meres degeneration morphologically visualized as necrotic
cells. Embryos were considered fully intact only if they have
100 % surviving cells. Surviving embryos were put overnight
in culture and only embryos that had cleaved were transferred.
Usually, single embryo transfer was performed except in low
prognosis cases were double transfer was allowed on patient
request. The mean number of embryos transferred (Irvine 1.2
±0.4; Vitrolife group 1.2±0.5; slow-freezing group 1.1±0.4)
was similar between the three different groups. The embryo
survival rate was calculated as the percentage of embryos
which survived after warming among the total number of
embryos warmed. The embryo cleavage rate was calculated
as the percentage of embryos which had cleaved among the
surviving embryos. Only clinical pregnancies certified by the
presence of at least one gestational sac at ultrasound were
taken into account for calculation of implantation rate per
transferred embryo as well as per warmed embryo. Live birth
rates were calculated as the percentage of live birth per trans-
ferred embryo and per warmed embryo.
Statistics
Data were compared with χ2-tests using StatCalc software.
Yates corrected p-values <0.05 were considered as being
significant.
Results
Results from the 1055 warmed embryos are summarised in
Table 1. Post-warming survival of embryos in both vitrification
methods were significantly higher compared to slow-freezing
(p <0.001). The proportion of embryos with 100 % intact
blastomeres after warming was significantly higher after vitri-
fication than after slow-freezing (p <0.001). The cleavage rates
of survived embryos after warming were significantly higher
with vitrification methods (Irvine: p <0.001; Vitrolife: p <0.05
respectively) compared to slow-freezing. A significant
difference in cleavage rate was observed between the two
vitrification methods (p <0.05) (Table 1).
Due to the higher post-warming survival and cleavage rate
of embryos, significantly more transfers per warming cycle
were performed when embryos were cryopreserved by both
vitrification methods compared to slow-freezing method
(p <0.001). As summarised in Table 2, significant difference
in the transfer rates per warming cycle was observed between
the two vitrification methods (p <0.05) (Table 2).
Implantation rate (IR) per embryo transferred and per em-
bryo warmed and live birth (LB) per transferred embryo and
per warmed embryo were no significant different (NS) be-
tween the three cryopreservation methods in the results ob-
tained on the study sample (Table 1).
Discussion
The slow-freezing method used for cryopreservtaion of hu-
man embryos has been largely used for cryopreservation of
human embryos and recent improved protocols have
optimised results [24, 25]. The vitrification is an increasingly
popular method, based on an extreme viscosity of cryoprotec-
tant solutions and a high cooling rate. To achieve the solidifi-
cation of the solution below the glass transition temperature,
high concentrations of cryoprotectants are used [33] and sam-
ples are loaded in a small volume. Different devices have been
developed to achieve high cooling rate minimizing the expo-
sure time to the vitrification solution [34–37]. If the exposure
to cryoprotectants is too long, embryos suffer from toxicity of
the solution [16–20]. For successful cryopreservation, an op-
timal balance between the cryoprotectant concentration and
the cooling rate has to be established, to minimize toxic and
osmotic injuries [38]. With recent improvements in media,
devices and protocols, vitrification has become a reliable
method. It is very simple and cheap; it can lead to high
survival rates and good clinical outcomes [39]. One of the
remaining concerns regarding vitrification is the possible toxic
effect of the different cryoprotectant required at high concen-
tration [40].
Technical outcomes of different methods for cryopreservation
of cleavage-stage human embryos
Results in survival and developmental rates aswell asmetabolic
analysis of embryos obtained with different methods were
evaluated and reported in the literature. In the study of Rama
Raju et al. (2005) [28], cleavage stage embryos were vitrified
using opened devices or conventional slow-freezing protocol.
Post-thaw survival rate was significantly higher for the vitrifi-
cation group compared to the slow-freezing group (p <0.05).
Later, Balaban et al. (2008) [29] cryopreserved cleavage stage
embryos, donated for research by either conventional slow-
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freezing or vitrification using opened devises. Significantly
more embryos survived after vitrification compared to slow-
freezing (p <0.05) and the progression rate to the blastocyst
stage was significantly higher after vitrification than after
slow-freezing (p =0.02). Furthermore, metabolic analysis
such as pyruvate uptake showed also a higher metabolic
rate, leading to greater developmental rate to the blastocyst
in the vitrification group. In a retrospective study, Rezazadeh
Valojerdi et al. (2009) [30] evaluated the efficacy of vitrifi-
cation using opened and slow-freezing for the cryopreserva-
tion of human cleavage stage embryos cryopreserved either
with vitrification or slow-freezing. The survival rate and the
post-warmed embryo morphology with all blastomeres intact
were higher in the vitrification compared to the slow-
freezing group confirming a minimal deleterious effect of
vitrification on post-warming embryo morphology. In the
study of Kartberg et al. (2008) [40], the authors evaluated
the effect of cryoprotectants reporting compromised develop-
mental ability if the cleavage stage embryos were vitrified
when exposed to cryoprotectants for too long. Recently,
Cobo et al. (2012) [41] assessed the embryo developmental
and quality in a large study including almost 4.000 embryos
when cryopreserved at different developmental stages and
vitrified using open devices. Regarding early cleavage em-
bryos, after warming, a very high number (~95 %) exhibited
100 % intact blastomeres after vitrification. In these studies,
the embryos were vitrified using differents protocols but
always by direct contact with liquid nitrogen. Even if there
is no evidence in the published reports about contamination
of cryopreserved embryos by direct contact with liquid ni-
trogen, devices such as Vitrification High Security kits from
CryoBioSystem have been designed to reduce potential
viral cross-contamination during storage in liquid nitro-
gen [42–45].
In our study, 1798 supernumerary good-quality cleavage
embryos were cryopreserved by two different vitrification
methods (DMSO-containing vs. DMSO-free vitrification so-
lutions) or slow-freezing and the storage in all groups was
performed in high security devices. In agreement with previ-
ous studies, results obtained on 1055 embryos showed that the
survival rate significantly higher in the vitrification groups
than in the slow-freezing group (p <0.001). The proportion of
embryos with 100 % intact blastomeres, and the cleavage rate
was significantly higher in the vitrification groups than in the
slow-freezing group (p <0.001). Significant difference in
cleavage rate was observed between the two vitrification
methods (p <0.05), which has never been reported in a
randomised clinical trial, suggesting that Irvine method
better preserve the embryo developmental competence
after warming.
Clinical outcomes of different methods for cryopreservation
of cleavage-stage human embryos
Results in implantation and live birth rates obtained with dif-
ferent methods were evaluated and reported in the literature.
Rama Raju et al. (2005) showed a higher IR in vitrification
Table 1 Summarised results of cryopreserved/warmed embryos by vitrification Irvine, vitrification Vitrolife and slow-freezing methods (IR implan-
tation rate; LB live birth rate)
Vitrification Irvine Vitrification Vitrolife Slow-freezing Total
Cryopreserved embryos 575 524 699 1798
Warmed embryos 330 330 395 1055
Survived embryos (%) 295/330 (89.4 %)a 289/330 (87.6 %)b 252/395 (63.8 %)a, b 836/1055 (79.2 %)
Fully intact embryos (%) 267/330 (80.1 %)a 251/330 (76.1 %)b 175/395 (44.3 %)a, b 693/1055 (65.7 %)
Cleaved embryos (%) 259/295 (87.8 %)a, c 235/289 (81.3 %)c, d 182/252 (72.2 %)a, d 676/836 (80.9 %)
Transferred embryos (%) 259/330 (78.5 %)a, c 235/330 (71.2 %)b, c 182/395 (46.1 %)a, b 676/1055 (64.1 %)
IR/transferred embryo (%) 41/259 (15.8 %) 40/235 (17 %) 39/182 (21.4 %) 120/676 (17.7 %)
IR/warmed embryo (%) 41/330 (12.4 %) 40/330 (12.1 %) 39/395 (9.8 %) 120/1055 (11.3 %)
LB/transferred embryo (%) 26/259 (10 %) 25/235 (10.6 %) 24/182 (13.2 %) 75/676 (11.1 %)
LB/warmed embryo (%) 26/330 (7.8 %) 25/330 (7.5 %) 24/395 (6.1 %) 75/1055 (7.1 %)
Data were compared between groups. P-values: a vs a <0.001; b vs b <0.001; c vs c <0.05; d vs d <0.05)
Table 2 Transfer rates per initiated warming cycle when embryos were








Initiated warming cycles 255 261 260
Transfer rate per initiated
warming cycle
86.3 % a,c 77.4 % b,c 61.1 % a, b
Mean number of embryos
transferred
1.2±0.4 1.2±0.5 1.1±0.4
Data were compared between groups. P-values: a vs a <0.001; b vs b
<0.001; c vs c <0.05)
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group compared to slow-freezing group of patients [28]. Later,
Balaban et al. (2008) [29] confirmed a high clinical implanta-
tion rate after transfer of vitrified-warmed embryos. Rezazadeh
Valojerdi et al. (2009) [30] also compared clinical outcomes
after transfer of vitrified and slow-freezed embryos. In these
studies patients were younger than in our study and 3 to 4
embryos cooled at day 3 with the best morphology were
selected at warming and cultured for transfer. The implantation
rate was higher in the vitrification group compared to slow-
freezing group but the incidence of multiple pregnancy rate was
also high. In the large study of Cobo et al. (2012) [41], the
number of embryos to be transferred varied with each case, but
typically 2 embryos were transferred on day 2 or day 3 and
elective SET was considered only for blastocyst stage. The
implantation rate of cleavage stage embryos was very high
(27.2 % and 34.6 % for day 2 and day 3 respectively). As
reported in these studies the clinical outcomes of the vitrifica-
tion seems to be highly variable according to the centers [46].
The differences in implantation rate observed in the literature
can be explained by many factors as the embryo selection for
freezing or the patient characteristics. It may also be related to
two major factors: the number of embryos warmed per cycle
giving or not the possibility to choose the surviving embryos for
transfer, and the use of different devices.
In our study, mostly SETwere performed to reduce the risk
of multiple pregnancy and closed devices were used to reduce
the risk for cross contamination, with the disadvantage to
slower vitrification speed compared to open devices [37–39,
43]. It may explain our lower clinical results compared to
previous large studies [41]. The implantation rate (IR) and
live birth (LB) rates per transferred embryo obtained were not
significantly different (NS) between the three cryopres-
ervation methods. Nevertheless, as the slow-freezing
method was less efficient regarding the embryo survival
and the fully intact survival rates, significantly more
transfers were performed when embryos were cryopre-
served by vitrification than by slow-freezing method.
Based on the differences observed in our results, a statistical
power calculation for the study size assessed the number of
embryos needed at more than 2500 to obtain significant
difference for the clinical outcomes.
Summarized results and new findings of our study
In conclusion, this study provides evidence that vitrification,
even in closed devices, is more efficient than slow-freezing
cryopreservation in terms of survival and developmental rates
of human cleavage embryos. Regardless of cryoprotectants
and their concentration, vitrification gives better embryo sur-
vival rate compared to slow-freezing. Results observed be-
tween vitrification methods, suggest that Irvine method
better preserve the embryo developmental competence
after warming.
Even if no significant differences in implantation rate and
live birth were observed between the three cryopreservation
methods, through a higher survival rate and quality of the
embryos at warming, vitrification may improve the clinical
outcome of IVF by maximizing the cumulative efficiency of
the cycle.
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